Oct 22, 2019

Decreased growth among antiretroviral drug and HIV exposed uninfected versus unexposed children in Malawi and Uganda

Jim AizirePROMISE-NEURODEV study team


To compare growth among antiretroviral drug and maternal-HIV exposed uninfected (AHEU) versus age-and-sex-matched HIV unexposed uninfected (HUU) children. Prospective cohort of AHEU children identified from the PROMISE trial (NCT01061151: clinicaltrials.gov registry) and age-and-sex-matched HUU controls from child-wellness clinics, enrolled (09/2013-10/2014) in Malawi and Uganda. Weight-for-age (WAZ), length-for-age (LAZ), weight-for-length (WLZ), and head-circumference-for-age (HCAZ) z-scores were derived at 12 and 24 months-of-age. Wilcoxon Rank-Sum and Fischer's exact tests were used for unadjusted exposure group comparisons. Generalized-Estimating-Equations models estimated adjusted relative risks (aRR) for poor growth outcomes. Overall, 471 (50.5%) AHEU and 462 (49.5%) HUU children were assessed. Ugandan AHEU compared to HUU children had significantly lower mean LAZ (p < 0.001) and WAZ (p < 0.001) at 12 and 24 months-of-age and HCAZ (p = 0.016) at 24 months, with similar but not significant differences among Malawian AHEU and HUU children. The risk of stunting (more than two standard deviations below the WHO-population LAZ median) was increased among AHEU versus HUU children: aRR = 2.13 (95% confidence interval (CI): 1.36,...Continue Reading

  • References22
  • Citations


  • This paper may not have been cited yet.

Mentioned in this Paper

Head Circumference
B-Cell Lymphoma 6 Protein
HIV Infections
World Health Organization
Pharmacologic Substance
Mann-Whitney Test
Clinical Trials
Population Group

Related Feeds

AIDS Malignancies

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.